AzTrials
AzTrials

Lung CancerPOLCAR-HVNCT07824544

An App to Identify Radiation Pneumonitis - a Pre-Study in Healthy Volunteers

A study testing PneumoCheck app in people with Lung Cancer, run by University Hospital Schleswig-Holstein at 1 site in Denmark.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record

Search all trials

Trial summary

Radiation pneumonitis is a possible side effect of radiotherapy for lung cancer. Since it often occurs only several weeks following radiotherapy, the corresponding symptoms may not be associated with previous administered radiotherapy. As a consequence, pneumonitis may be diagnosed very late or even be missed. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Lung Cancer
What is being tested?
PneumoCheck app
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
1 siteDenmark
Study dates
28 Sep 2026to 31 Oct 2026
Phase
Interventional

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Possession of and ability to use a smart phone
  • Age ≥18 years
  • Written informed consent
  • Capacity of the participant to consent

Who cannot join

  • 1. Expected non-compliance

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Dirk Rades, Prof. Dr. med., FASTRO contact

0049-451-500 ext. 45400

Dirk.Rades@uksh.de

Maria K Streubel, Dr. rer. nat. contact

0049-451-500 ext. 45420

MariaKarolin.Streubel@uksh.de

Denmark1 site
  • Department of Oncology Vejle Hospital, University Hospital of Southern Denmark

    Vejle, 7100

    Charlotte Kristiansen, MD, 0045-7940 ext. 6094, charlotte.kristiansen@rsyd.dk

Other trials in Denmark

About this study

Official title: An App to Identify Radiation Pneumonitis in Lung Cancer Patients - a Pre-Study in Healthy Volunteers

Radiation pneumonitis is a possible side effect of radiotherapy for lung cancer. Since it often occurs only several weeks following radiotherapy, the corresponding symptoms may not be associated with previous administered radiotherapy. As a consequence, pneumonitis may be diagnosed very late or even be missed. Based on the findings of two prospective trials, a mobile application (PneumoCheck) has been developed, which can be used by the patients at home. This app may contribute to an earlier detection of radiation pneumonitis. Before this app can be tested in patients, its usability needs to be evaluated by healthy volunteers. In the present prospective study, 30 healthy volunteers test and rate the usability of the app. The healthy volunteers have to download the PneumoCheck app, which has been designed by the Luebeck based company Nextlabel Offene Handelsgesellschaft (OHG). After receiving the link for the download of the app from Nextlabel OHG by e-mail, the participants are asked to test the app and complete a questionnaire. They are asked to affirm or negate ten statements in three sections (download and installation, navigation, and content/functions) regarding the usability of the app. The satisfaction rate represents the rate of participants who affirmed a statement. If this rate was <60%, the app was rated as not being useful. If the rate was between ≥60% but <80%, the app was regarded useful but required further optimization regarding the corresponding section. In addition, iPhone and Android users are compared with respect to the satisfaction rates (Fisher's exact tests).

Read the detailed description

Lung cancer belongs to the most common types of solid cancer in Europe and Northern America. Most patients with small-cell lung cancer receive radiotherapy in combination with chemotherapy as definitive treatment. Also, a considerable number of patients with advanced non-small-cell lung cancer are treated with radiotherapy with or without concurrent chemotherapy. Radiation pneumonitis is a possible side effect of radiotherapy for lung cancer. Severe pneumonitis was reported to be fatal in approximately 2% of patients experiencing this adverse event. Pneumonitis may occur only several weeks or even months following radiotherapy. The symptoms may not be associated with the previously administered radiation treatment, and pneumonitis may be missed. Symptoms of pneumonitis generally include cough, shortness of breath, and fever. In a previous prospective trial (PARALUC), a scoring system was developed to contribute to a more precise and earlier detection of symptomatic radiation pneumonitis (grade ≥2) after radiotherapy for lung cancer. In that trial, 0 to 3 scoring points were assigned to each of the three symptoms mentioned above. Thus, patient scores ranged between 0 and 9 points. The optimal cut-off score for identification of pneumonitis was found to be 5 points. Moreover, an increase by 3 or more points from the baseline score was significantly associated with pneumonitis. Since the PARALUC trial was performed in lung cancer patients of any age, it was not clear whether its results were applicable to elderly patients known to have a higher risk of developing pneumonitis. Therefore, the POLCAR trial was performed in lung cancer patients aged ≥65 years. In that trial, the optimal cut-off score for identification of pneumonitis was 4 points, and an increase by 2 or more points compared to baseline was associated with pneumonitis. Based on the results from the PARALUC and the POLCAR trial, an app (PneumoCheck) was developed. Before this app can be tested in a prospective trial involving patients, its usability needs to be evaluated by healthy volunteers. In the present prospective study, 30 healthy volunteers test and rate ten aspects related to the usability of the app.

This is a prospective multi-center study (one arm), which is performed in 30 healthy volunteers. Inclusion criteria are possession of and ability to use a smart phone, age of at least 18 years, written informed consent, and capacity of the participant to consent. Patients with expected non-compliance will not be included. The healthy volunteers have to download the PneumoCheck app, which has been designed by the Lübeck based company Nextlabel OHG. After receiving the link for the download of the app from Nextlabel OHG by e-mail, the participants are asked to test the app and complete a questionnaire. They are asked to affirm or negate ten statements in three sections (download and installation, navigation, and content/functions) regarding the usability of the app. Recruitment of all participants should be completed within 1 month. The study for each participant takes only 1 day. Thus, the expected total running time for this study is 1 month. The primary objective of this study is to evaluate the usability of the PneumoCheck app designed to identify radiation pneumonitis in lung cancer patients. Primary endpoint is satisfaction with the PneumoCheck app. In addition, iPhone and Android users will be compared.

The participants have to download the app, which has been designed by the Luebeck based company Nextlabel OHG. After receiving the link for the download of the app from Nextlabel OHG by e-mail, the participants are asked to test the app and complete a questionnaire (according to previous studies, Appendix III). They are asked to affirm or negate ten statements in three sections (download and installation, navigation, and content/functions) regarding the usability of the app. The satisfaction rate represents the rate of participants who affirmed a statement. If this rate was <60%, the app was rated as not being useful. If the rate was between ≥60% but <80%, the app was regarded useful but required further optimization regarding the corresponding section. In addition, iPhone and Android users are compared with respect to the satisfaction rates (Fisher's exact tests).

Conditions
Lung Cancer
Being tested
PneumoCheck app
Keywords
Lung cancer, Radiotherapy, Radiation pneumonitis, Early diagnosis, Mobile application
Medical subject headings
Lung Neoplasms, Radiation Pneumonitis, Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PneumoCheck appDevice

    The healthy volunteers have to download the PneumoCheck app, which has been designed by the Lübeck based company Nextlabel OHG. After receiving the link for the download of the app from Nextlabel OHG by e-mail, the participants are asked to test the app and complete a questionnaire. They are asked to affirm or negate ten statements in three sections (download and installation, navigation, and content/functions) regarding the usability of the app.

Study groups in NCT07824544
Study groupRoleWhat they receive
Healthy volunteers evaluating an appExperimentalArm Description: Participants are asked to test an app designed to contribute to the detection of radiation pneumonitis and complete a questionnaire. They are asked to affirm or negate ten statements in three sections (download and installation, navigation, and content/functions) regarding the usability of the app.
Receives: Device: PneumoCheck app

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Satisfaction with the PneumoCheck app

    The participants are asked to affirm or negate ten statements in three sections (download and installation, navigation, and content/functions) regarding the usability of the PneumoCheck app. The satisfaction rate represents the rate of participants who affirmed a statement. If this rate was <60%, the reminder app was rated as not being useful. If the rate was between ≥60% but <80%, the app was regarded useful but required further optimization regarding the corresponding section.

    Measured: 1 day

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Sep 2026
  2. Study start28 Sep 2026 (estimated)
  3. Primary completion31 Oct 2026 (estimated)
  4. Study completion31 Oct 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Model description
This is a prospective multi-center study (one arm), which is performed in 30 healthy volunteers.
Masking
None (open label)
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07824544
Sponsor's protocol ID
POLCAR-HV
Acronym
POLCAR-HV
Status last verified
Sep 2026
First submitted
11 Sep 2026
Last updated
17 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in